RenovoRx, Inc. — Investor Relations & Filings
RenovoRx, Inc. is a clinical-stage life sciences company developing targeted oncology therapies for solid tumors. The company's core technology is its proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform, which is designed for the localized delivery of therapeutic agents directly to tumors. This approach aims to enhance treatment efficacy while minimizing the systemic toxicities associated with conventional intravenous chemotherapy. The TAMP platform is enabled by the RenovoCath®, an FDA-cleared dual-balloon infusion catheter that isolates blood flow for targeted drug delivery. RenovoRx is advancing its lead drug-device combination product candidate in the Phase III TIGeR-PaC clinical trial for the treatment of locally advanced pancreatic cancer.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-K/A | 2026-05-15 | English | |
| 8-K | 2026-05-14 | English | |
| DEF 14A - RenovoRx, Inc. (0001574094) (Filer) | 2026-04-30 | English | |
| 424B3 - RenovoRx, Inc. (0001574094) (Filer) | 2026-04-27 | English | |
| S-3 - RenovoRx, Inc. (0001574094) (Filer) | 2026-04-16 | English | |
| 4 - RenovoRx, Inc. (0001574094) (Issuer) | 2026-03-27 | English |
Browse filings by year
9 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46363239 | 10-K/A | 2026-05-15 | English | ||
| 46274549 | 8-K | 2026-05-14 | English | ||
| 39207996 | DEF 14A - RenovoRx, Inc. (0001574094) (Filer) | 2026-04-30 | English | ||
| 37646430 | 424B3 - RenovoRx, Inc. (0001574094) (Filer) | 2026-04-27 | English | ||
| 34650376 | S-3 - RenovoRx, Inc. (0001574094) (Filer) | 2026-04-16 | English | ||
| 33058807 | 4 - RenovoRx, Inc. (0001574094) (Issuer) | 2026-03-27 | English | ||
| 33058608 | 3/A - RenovoRx, Inc. (0001574094) (Issuer) | 2026-03-27 | English | ||
| 33058261 | 8-K - RenovoRx, Inc. (0001574094) (Filer) | 2026-03-27 | English | ||
| 33036308 | 4 - RenovoRx, Inc. (0001574094) (Issuer) | 2026-03-25 | English | ||
| 33036307 | 4 - RenovoRx, Inc. (0001574094) (Issuer) | 2026-03-25 | English | ||
| 33036306 | 4 - RenovoRx, Inc. (0001574094) (Issuer) | 2026-03-25 | English | ||
| 33036294 | 3 - RenovoRx, Inc. (0001574094) (Issuer) | 2026-03-25 | English | ||
| 33012729 | 8-K - RenovoRx, Inc. (0001574094) (Filer) | 2026-03-23 | English | ||
| 30649394 | 8-K Filing | 2026-02-06 | English | ||
| 30649391 | SCHEDULE 13G/A Filing | 2026-01-30 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
RenovoRx, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34656/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34656 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34656 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34656 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34656}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for RenovoRx, Inc. (id: 34656)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.